ALK-Abelló’s Acarizax meets primary endpoint in China Phase 3 allergy trial

• ALK-Abelló announced positive Phase 3 results for ACARIZAX in China, meeting the trial’s primary objective in patients with house dust mite allergy.
• The treatment reduced allergic rhinitis symptoms versus placebo and was safe and well tolerated, consistent with previous trials.
• Regulatory filing in China is expected in the first half of 2027 through partner GenSci.
• The results do not affect ALK’s 2026 financial guidance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALK-Abelló A/S published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.